Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GCK | P35557 | 19/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272234 | 0.86 | CYP17A1 (0.52) | CYP17A1CYP1A2GCKKCNH2 | |
| SCHEMBL838627 | 0.86 | CYP17A1 (0.49) | CYP17A1CYP1A2 | |
| SCHEMBL839952 | 0.80 | MAPK14 (0.47) | CYP1A2GCKKCNH2 | |
| SCHEMBL12000878 | 0.80 | ALDH1A1 (0.41) | CYP1A2 | |
| SCHEMBL839210 | 0.79 | GCK (0.47) | CYP1A2GCKKCNH2 | |
| SCHEMBL839539 | 0.78 | XDH (0.38) | CYP17A1CYP1A2 | |
| SCHEMBL840321 | 0.78 | GSK3B (0.52) | CYP17A1CYP1A2 | |
| SCHEMBL838336 | 0.77 | TP53 (0.41) | CYP17A1CYP1A2 | |
| SCHEMBL6071536 | 0.77 | GSK3B (0.54) | CYP17A1CYP1A2 | |
| SCHEMBL838829 | 0.77 | P2RX7 (0.46) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | CYP17A1 1126/4885CYP1A2 3364/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.